Company intelligence / Profile preview

Daisy Pharma Opioid Venture

Ownership: Private
Development stage: Other

Overview

Daisy Pharma is a pharmaceutical company focused on developing innovative treatments for opioid-related conditions, including opioid use disorder and overdose prevention. The company is known for its 'Opioid Venture,' which aims to create safer alternatives and rescue medications to combat the global opioid crisis. Their research primarily centers on small molecule modulators of opioid receptors designed to reduce the risk of respiratory depression while maintaining therapeutic efficacy. Daisy Pharma operates as a private entity, leveraging specialized expertise in medicinal chemistry and neuropharmacology.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Daisy Pharma Opioid Venture.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daisy Pharma Opioid Venture.

Explore the full profile